Navigation Links
$2.3 million in NIH funding for promising cancer research at Cincinnati Children's
Date:4/15/2010

CINCINNATI Two scientific teams at Cincinnati Children's Hospital Medical Center are receiving a total of $2.3 million in research funding from the National Institutes of Health (NIH) to continue promising studies seeking novel treatments for leukemia and bone marrow failure.

A team led by Yi Zheng, Ph.D., and James Mulloy, Ph.D., is getting a five-year grant totaling $1.04 million from NIH's National Cancer Institute entitled, "Targeting CDC42 in Leukemia Stem Cells." Qishen Pang, Ph.D., and colleagues are being awarded a five-year grant totaling $1.25 million from the National Heart, Lung and Blood Institute entitled, "Role of FA Protein Complexes in Hematopoiesis."

The scientists are all part of the Cancer and Blood Diseases Institute at Cincinnati Children's and its divisions of Experimental Hematology/Cancer Biology and Hematology/Oncology. Dr. Zheng is director of Experimental Hematology/Cancer Biology.

Research into CDC42 involves a protein that normally is crucial to cell adhesion, survival and migration. Scientists have learned that under certain conditions CDC42 stimulates development of disease initiating cells in bone marrow and leukemia stem cells, which they believe can fuel prolonged disease, relapse and mortality. The research team has been studying this process in Acute Myeloid Leukemia (AML), a complex blood cancer that often suffers from relapse after conventional chemotherapy treatment.

Ongoing studies of mice bred to model human leukemia including a novel mouse model of AML developed by Dr. Mulloy's laboratory and of human leukemia cells have shown blocking CDC42 inhibits formation of cells that initiate leukemia and promotes programmed cell death of leukemia cells. The goal of the newly funded research is to develop a new therapeutic strategy for targeting CDC42 to eliminate leukemia stem cells in bone marrow for leukemias that are resistant to conventional chemotherapies.

Dr. Pang's team is studying molecular mechanics of how Fanconi anemia (FA) proteins regulate cell response to oxidative stress during hematopoiesis, the process of blood cell formation in bone marrow. This is important to understanding the progression Fanconi anemia, bone marrow failure, myelodisplastic syndrome (once called pre-leukemia), AML and the underlying genomic instability in people with Fanconi anemia.

The researchers have already shown that bone marrow cells from patients with Fanconi anemia accumulate high levels of molecules called reactive oxygen species (ROS). ROS molecules are the source of oxidative stress and bone marrow cells in people with Fanconi anemia are sensitive to ROS suppressing the formation of blood stem and progenitor cells. The scientists have also demonstrated that abnormal accumulation of ROS leads to formation of leukemic cells in a mouse model of Fanconi anemia. The team has reported that a specific FA protein, FANCD2, binds and works with the transcription factor FOXO3a, which helps control the transfer of genetic information in cellular stress response processes. Together hey form a complex that helps provide a cellular defense system against oxidative stress.

By using cells from children with Fanconi anemia and working with mouse models in their continued research, the scientists hope to find new therapeutic targets to treat or prevent bone marrow failure and related cancer progression.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related biology news :

1. Structure of 450 million year old protein reveals evolutions steps
2. First orchid fossil puts showy blooms at some 80 million years old
3. SyntheMed Completes $2.8 Million Equity Financing
4. Rutgers Genetics receives $7.8 million for autism research
5. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
6. UD leads $5.3-million research project on rice epigenetics
7. Rutgers high school outreach gets $3 million boost from NSF
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. UD leads $5.3-million research project on rice epigenetics
10. $22 million gift from Alfred Taubman launches new biomedical research institute
11. Nanobiosym awarded $2 million DTRA contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... February 04, 2016 , ... ... Forensics Club, takes place February 5-6 at the University’s student center, Kehr ... activities such as workshops and competitions for ample networking, learning and collaborating ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
(Date:2/4/2016)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today provided an update on the Company,s ... of Texas and announcing that ... Partes Re-examination ("IPR") proceedings that VTech and Uniden ... initiated on only certain claims of two of the ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology: